Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled Phase III study of bempedoic acid tablets in patients with inadequately controlled hyperlipidemia
CTR20251629Phase 3Active
- Sponsor
- Hefei Lifeon Pharmaceutical
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bempedoic acid in hyperlipidemia, familial hypercholesterolemia (FH), atherosclerotic disease, Not applicable, sponsored by Hefei Lifeon Pharmaceutical. Started Apr 2025; status: active.
02
Drugs
bempedoic acid
03
Conditions
hyperlipidemiafamilial hypercholesterolemia (FH)atherosclerotic diseaseNot applicable
Beyond the preview
Go deeper on CTR20251629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251629.